Mundipharma's bendamustine plus rituximab doubles PFS in non-Hodgkin ... The Pharma Letter Results from the StiL NHL-1 study published in the Lancet today (February 20) show that a first-line treatment regimen of bendamustine (marketed under the trade name Levact by privately-held Swiss drugmaker Mundipharma) plus rituximab (B-R) doubles ... |
